Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy VBI Vaccines stock
Learn how to easily invest in VBI Vaccines stock.
VBI Vaccines Inc is a biotechnology business based in the US. VBI Vaccines shares (VBIV) are listed on the NASDAQ and all prices are listed in US Dollars. VBI Vaccines employs 127 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in VBI Vaccines
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – VBIV – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
VBI Vaccines stock price (NASDAQ: VBIV)Use our graph to track the performance of VBIV stocks over time.
VBI Vaccines shares at a glance
|Latest market close||$1.53|
|52-week range||$1.74 - $4.83|
|50-day moving average||$2.47|
|200-day moving average||$3.00|
|Wall St. target price||$7.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.26|
Buy VBI Vaccines shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy VBI Vaccines stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
VBI Vaccines price performance over time
|1 week (2022-01-21)||-12.07%|
|1 month (2021-12-28)||-30.77%|
|3 months (2021-10-28)||-49.00%|
|6 months (2021-07-28)||-50.16%|
|1 year (2021-01-28)||-53.07%|
|2 years (2020-01-28)||8.51%|
|3 years (2019-01-28)||1.54|
|5 years (2017-01-27)||3.8|
VBI Vaccines financials
|Gross profit TTM||$-8,107,000|
|Return on assets TTM||-18.1%|
|Return on equity TTM||-40.7%|
|Market capitalisation||$447.7 million|
TTM: trailing 12 months
VBI Vaccines share dividends
We're not expecting VBI Vaccines to pay a dividend over the next 12 months.
Have VBI Vaccines's shares ever split?
VBI Vaccines's shares were split on a 1:40 basis on 1 May 2016. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VBI Vaccines shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for VBI Vaccines shares which in turn could have impacted VBI Vaccines's share price.
VBI Vaccines share price volatility
Over the last 12 months, VBI Vaccines's shares have ranged in value from as little as $1.74 up to $4.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VBI Vaccines's is 1.8454. This would suggest that VBI Vaccines's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
VBI Vaccines overview
VBI Vaccines Inc. , a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901.
VBI Vaccines in the news
VBI Vaccines to Participate in the B. Riley Securities 2022 Oncology Investor Conference
VBI Vaccines : to Participate in the B. Riley Securities 2022 Oncology Investor Conference - Form 8-K
VBI VACCINES INC/BC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Frequently asked questionsWhat percentage of VBI Vaccines is owned by insiders or institutions?
Currently 0.524% of VBI Vaccines shares are held by insiders and 47.569% by institutions. How many people work for VBI Vaccines?
Latest data suggests 127 work at VBI Vaccines. When does the fiscal year end for VBI Vaccines?
VBI Vaccines's fiscal year ends in December. Where is VBI Vaccines based?
VBI Vaccines's address is: 222 Third Street, Cambridge, MA, United States, 02142 What is VBI Vaccines's ISIN number?
VBI Vaccines's international securities identification number is: CA91822J1030 What is VBI Vaccines's CUSIP number?
VBI Vaccines's Committee on Uniform Securities Identification Procedures number is: 91822J103
More guides on Finder
Cathie Wood’s ARK analysts predict Bitcoin at $1 million each by 2030
Five major factors contribute to the continued bull run of Bitcoin, ARK says, including growing adoption and long-term focus of investors.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Stocks are dropping; 3 rules for buying on the dip
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market has lost $1.5 trillion in value — time to buy?
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin tumbles past $40,000, altcoins follow
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s Pavia plot sale shows land rush is on in the metaverse
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Today’s top U.S. stocks: Mechel Pao ADRs (MTL ↑8.1%), Sibanye-Stillwater Limited (SBSW ↑7.4%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
How to order free at-home COVID tests today — but note, there’s a wait
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
Ask an Expert